Efficacy and Safety of Tixel Treatment on Facial and/or Scalp Actinic Keratoses.

N

Novoxel

Status

Completed

Conditions

Actinic Keratoses

Treatments

Device: Tixel C

Study type

Interventional

Funder types

Industry

Identifiers

NCT05365386
CLN 0827

Details and patient eligibility

About

Evaluation of the Efficacy and Safety of a thermal fractional skin treatment system (Tixel) for the treatment of facial and/or scalp actinic keratoses

Full description

Single-center, Prospective, Open-Label, with Before-After Study Design. Up to 25 subjects will be enrolled to the study to provide at least 20 evaluable subjects. Subjects will be examined to determine the severity and extent of actinic keratoses. All subjects will undergo 1-3 treatments (determined by the investigator assessment), 3-4 weeks apart. Follow-up visits will be performed after the last treatment visit: 4 weeks (±7 days) and 12 weeks (±7 days). The inclusion criteria would be mild to moderate thickness confluent actinic keratoses located to scalp and/or face. Each subject will participate in the study for up to 20 weeks. Total study duration is estimated to be up to 12 months from enrollment of the first subject until last subject visit (including FUs).

Enrollment

20 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male and female, age 18-80 years old.
  • Skin Phototype I-VI.
  • Subject has mild to moderate thickness confluent AKs on his/her scalp and/or face.
  • Subject is willing and able to comply with protocol requirements and all study visits.
  • Subject has provided written informed consent.

Exclusion criteria

  • Any patient who has undergone tanning during the 4 weeks prior to any treatment session and/or any patient who plans to undergo tanning during the 4 weeks following any treatment session (patients who may be exposed to the sun for short periods of time occasionally are not contra-indicated as long as they apply a high SPF sunscreen (>50).
  • Current active Herpes Simplex infection.
  • Current skin cancer, malignant sites and/or advanced premalignant lesions or moles in the treatment area.
  • An impaired immune system condition or use of immunosuppressive medication.
  • Collagen disorders, keloid formation and/or abnormal wound healing.
  • Any patient who takes or has taken any medications (including via topical application), herbal treatment (oral or topic), food supplements or vitamins, which may cause fragile skin or impaired skin healing during the last 3 months.
  • Any patient who has used oral retinoids within 6 months prior to treatment or less.
  • Any patient who has a history of bleeding coagulopathies.
  • Any patient who has tattoos or permanent makeup in the treated area.
  • Any patient who has burned skin, blistered skin, irritated skin, or sensitive skin in any of the areas to be treated.
  • Women who are pregnant (as determined by self-reporting), lactating, or less than 3 months post-delivery, possibly pregnant or planning a pregnancy during the study period.
  • Currently participating in or recently participated in another clinical trial (within the last 30 days).
  • Prior treatment with ablative laser, any laser or photo-dynamic therapy 3 months prior to enrollment.
  • Any cryotherapy or electrodessication 6 weeks prior to enrollment.
  • Systemic retinoid therapy within 6 months prior to enrollment, topical treatment with 5-Fluorouracil cream and/or imiquimod cream and/or diclofenac gel 6 months prior to enrollment.
  • Prior treatment with Tixel.
  • Face cannot be treated due to dermal disorder other than AKs, such as infection, surgical treatment etc.
  • Subject has a systemic disease manifested by AKs (e.g. immune suppression).
  • Significant systemic illness.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

Tixel Treatment
Experimental group
Description:
All subjects will undergo 1-3 treatments (determined by the investigator assessment), 3-4 weeks apart with the Tixel device.
Treatment:
Device: Tixel C

Trial contacts and locations

1

Loading...

Central trial contact

Ifat Klein, P.hd; Hila Kfir, b.sc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems